CRBU
Caribou Biosciences, Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Feb 24 to Feb 25 ▼ 2 days of insider sells: $47.5K by 4 insiders, avg $1.95
- Mar 5 Caribou Biosciences reported fourth quarter and full-year 2025 finan…
- Jun 11 FDA: Caribou Biosciences Reports Dose Escalation Durability Dat…
- Jun 11 ▲ Caribou Biosciences announced long-term follow-up data from its ANTL…
- Jun 11 ▲ Caribou Biosciences reported longer follow-up data from the CaMMoufl…
- Oct 6 ▼ Caribou Biosciences is discontinuing its two allogeneic CAR-T cell t…
- Oct 7 ▼ 3 downgrades
- Oct 8 ▼ HC Wainwright & Co. downgrades
- Nov 5 ▼ Caribou Biosciences reported Q3 2026 revenue of $1.6M (below $2.2M a…
Signal stack
Where each data set points today.
- InsidersBEARISH
4 insiders sold $47.5K.
- InstitutionsBULLISH
Q3 2026: 20 added (0 new), 9 trimmed or exited.
- AnalystsBULLISH
8 of 12 rate it Buy or better. Every target is above the price.
- EstimatesRISING
Current-quarter EPS estimate −$0.360 → −$0.278 over 90 days. 1 up, 0 down in 30 days.
- Short sellersBUILDING
Short interest +18.6% to 14.89M shares. 6.0 days to cover, ≈13.8% of shares.
- TrendDOWNTREND
56% below its 50-day average. New closing low $0.3530 on Nov 16.
- SocialQUIET
No Reddit mentions this week. Last mention Nov 6.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| Qube Research & Technologies Ltd | DOUBLED | $1.4M |
| FMR LLC | ADD | $1.4M |
| UBS Group AG | ADD | $1.0M |
| MORGAN STANLEY | DOUBLED | $845.5K |
| MARSHALL WACE, LLP | ADD | $730.5K |
| Nuveen, LLC | ADD | $259.2K |
| Quadrature Capital Ltd | ADD | $187.2K |
| BARCLAYS PLC | DOUBLED | $165.1K |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
12 analystsPrice is below the lowest target. Median implies +183%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Oct 8, 2026 | HC Wainwright & Co. DOWNGRADE | Neutral |
| Oct 7, 2026 | Brookline Capital DOWNGRADE | Hold |
| Oct 7, 2026 | RBC Capital DOWNGRADE | Sector Perform |
| Oct 7, 2026 | Leerink Partners DOWNGRADE | Market Perform |
| Aug 14, 2026 | B of A Securities MAINTAIN | Buy |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Kelly Timothy P Chief Technology Officer Feb 25, 2026 | SELL | $12.0K |
MCCLUNG BARBARA G Chief Legal Officer Feb 24, 2026 | SELL | $13.6K |
Kelly Timothy P Chief Technology Officer Feb 24, 2026 | SELL | $6.2K |
Khan Ruhi Ahmad Chief Business Officer Feb 24, 2026 | SELL | $13.6K |
Albertson Tina M. Chief Medical Officer Feb 24, 2026 | SELL | $2.1K |
GUGGENHIME ANDREW Director Feb 20, 2026 | AWARD | 45,000 sh |
Sacks Natalie Director Feb 20, 2026 | AWARD | 45,000 sh |
MCCLUNG BARBARA G Chief Legal Officer Feb 20, 2026 | AWARD | 202,500 sh |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$0.28 | -$0.34–-$0.20 | +23.4% | $20.6M |
| Next Q | None | None | No data | $0.00 |
| Current FY | -$1.03 | -$1.10–-$0.94 | +11.9% | $25.7M |
| Next FY | -$0.65 | -$1.23–-$0.32 | +45.4% | $24.8M |
Short side
FINRA· Oct 30, 2026SecBot reports
11 filings · 2 press releases · 1 bullish · 2 bearish · 2 mixed · 6 neutral- BEARISH 8-KNov 5, 2026
Caribou Biosciences reported Q3 2026 revenue of $1.6M (below $2.2M a year ago) and a GAAP net loss…
The strategic alternatives process is open-ended with no timeline. Watch for any definitive agreement, asset sale, or dissolution plan. The cash runway of $94.8M provides some time but the company…
- BEARISH 8-KOct 6, 2026
Caribou Biosciences is discontinuing its two allogeneic CAR-T cell therapy programs (vispa-cel and…
The company is effectively winding down its core pipeline and pursuing a sale or merger. The $113.8M cash position provides a limited runway for the strategic review process. Watch for any…
- MIXED INST-CLUSTERSep 22, 2026
In Q2 2026, 26 institutional buyers accumulated $10.2M in CRBU (net +$4.7M), while 6 sellers…
The divergence between passive buying (Geode, Northern Trust, UBS) and active/quant selling (Millennium, Marshall Wace, Citadel, Point72, Susquehanna) suggests the stock is being accumulated by…
- BULLISH 8-KJun 11, 2026
Caribou Biosciences announced long-term follow-up data from its ANTLER phase 1 (vispa-cel…
The vispa-cel 2L LBCL data (82% ORR, 17.1-month mPFS) strengthen the case for the pivotal ANTLER-3 phase 3 trial, which targets an underserved patient population. The CB-011 MM data (83% CR, early…
All CRBU filing & press-release reports (13)
- 8-K reportNov 5, 2026
- 8-K reportOct 6, 2026
- INST-CLUSTER reportSep 22, 2026
- 8-K reportJun 11, 2026
- PRESS-RELEASE reportJun 11, 2026
- DEFA14A reportJun 5, 2026
- DEFA14A reportApr 24, 2026
- 8-K reportMar 5, 2026
- PRESS-RELEASE reportMar 5, 2026
- INST-CLUSTER reportFeb 28, 2026
- CLUSTER reportFeb 24, 2026
- CLUSTER, CLUSTER reportFeb 24, 2026
- CLUSTER reportFeb 24, 2026